The Chinese medicine JC-001 enhances the chemosensitivity of Lewis lung tumors to cisplatin by modulating the immune response

BMC Complementary and Alternative Medicine

Research Article

Ming-Shiou Jan¹  Meng-Hsien Chuang²  Jinghua Tsai Chang³  Fung-Jou Lu⁴ 

[1] Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, No.110, Sec.1, Jianguo N. Rd, 40201, Taichung City, Taiwan;Immunology Research Center, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. Rd, 40201, Taichung City, Taiwan;Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chung Shan Medical University Hospital, 110, Sec.1, Jianguo N. Rd, 40201, Taichung City, Taiwan;Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. Rd, 40201, Taichung City, Taiwan;Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. Rd, 40201, Taichung City, Taiwan;Department of Chest Medicine, Chung Shan Medical University Hospital, No. 110, Sec. 1, Jianguo N. Rd, 40201, Taichung City, Taiwan;Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. Rd, 40201, Taichung City, Taiwan;Department of Medical Research, Chung Shan Medical University Hospital, No. 110, Sec. 1, Jianguo N. Rd, 40201, Taichung City, Taiwan;

关键词: CDDP;    Lung cancer;    Immune;    Chemosensitivity;   

DOI  :  10.1186/s12906-017-1728-x

 received in 2017-01-14, accepted in 2017-04-05,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundJC-001 is a Chinese medicine that can modulate the immunity in Hepa 1-6 tumor-bearing mice, and we questioned whether JC-001 can serve as efficient adjuvant chemotherapy. We aimed to identify a novel approach for enhancing cis-diamminedichloroplatinum (II) (CDDP)-based chemotherapy by immunomodulation.MethodsThe anti-tumor activity in vitro was determined based on foci formation and a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A LLC1 tumor xenograft model was used to analyze the activity of tumor rejection in vivo. The tumors were analyzed through hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC) staining and cytokine arrays.ResultsJC-001 suppressed foci formation and reduced the viability of Lewis lung carcinoma (LLC1) cells in vitro. JC-001 suppressed LLC1 tumor growth in immunodeficient BALB/c nude mice and in immunocompetent C57BL/6 mice to an even greater extent. Furthermore, JC-001 up-regulated interferon-γ expression in the tumor microenvironment, enhanced the Th1 response in tumor-bearing mice, and increased the chemosensitivity of LLC1 tumors to CDDP chemotherapy. The results of our study suggest that JC-001 is associated with low cytotoxicity and can significantly suppress tumor growth by enhancing the Th1 response.ConclusionJC-001 is a Chinese medicine with potential clinical applications in CDDP-based chemotherapeutic regimens.

【 授权许可】

CC BY   
© The Author(s). 2017